Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$250.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Zealand Pharma A/S Announces Peptide Drug Research and Development Collaboration Agreement with Eli Lilly and Company


Thursday, 29 Aug 2013 07:52am EDT 

Zealand Pharma A/S announced an exclusive peptide drug research and development collaboration agreement with Eli Lilly and Company (Lilly). Under the agreement, Zealand will collaborate with Lilly in the design and development of peptide therapeutics for the treatment of Type 2 diabetes and obesity based on a novel approach discovered by Lilly. The companies will share in the funding, risk and reward of the program. Future expansion of the collaboration to additional drug targets and disease areas is possible. No financial terms of the agreement have been disclosed.